Pari Mody practices at the intersection of law and public policy, representing clients across the life sciences sector, including small- and mid-size biotechs, established drug and device manufacturers, and trade associations. Her practice focuses primarily on issues related to pharmaceutical pricing, Medicare and Medicaid coverage and reimbursement, and the 340B Program. Pari has particular expertise with emergent drug pricing initiatives, including the Inflation Reduction Act of 2022, most-favored-nation drug pricing models, and state Prescription Drug Affordability Boards.
Pari is adept at navigating the legislative and regulatory processes, drafting legislative language, preparing comment letters, and developing and implementing legislative and regulatory strategies. She also frequently advises clients on administrative law matters, including Administrative Procedure Act litigation.
Experience
- Advise pharmaceutical manufacturers on implementation of the Inflation Reduction Act of 2022, including negotiation strategies, data submissions, maximum fair price effectuation, and litigation matters.
- Counsel clients most-favored-nation drug pricing policies, including the GLOBE, GUARD, and GENEROUS models.
- Advise manufacturers and
trade associations on pending federal- and state-level legislation and regulatory reforms, including assessing legal impacts, drafting amendments and comment letters, and meeting with governmental officials. - Represented pharmaceutical manufacturers in Congressional investigations and oversight hearings related to drug pricing.
Perspectives
Recognition
Credentials
Education
- J.D., University of Maryland Francis King Carey School of Law, magna cum laude, Order of the Coif
- B.A., Oberlin College, high honors
Admissions
- District of Columbia
- Maryland
- U.S. District Court, District of Columbia